




# **Health Canada**

Fees Report Fiscal Year 2021-22

The Honourable Jean-Yves Duclos, P.C., M.P. Minister of Health





# Table of contents

| Minister's message   | 4   |
|--|-----|
| About this report  | 5   |
| Remissions   | 6   |
| Overall totals, by fee setting mechanism                                   | 7   |
| Totals, by fee grouping, for fees set by act, regulation or fees notice    | 7   |
| Details on each fee set by act, regulation or fees notice                  | 10  |
| Fees for Right to Sell Drugs   | 11  |
| Fees for Right to Sell a Licensed Class II, III or IV Medical Device       | 13  |
| Fees for Examination of a Submission — Drugs for Human Use                 | 14  |
| Certificate of Supplementary Protection Application Fees                   | 26  |
| Fees for Examination of an Application for a Medical Device Licence        | 27  |
| Fees for Examination of a Submission — Drugs for Veterinary Use Only       | 37  |
| Drug Establishment Licensing Fees  | 60  |
| Drug Establishment Licensing Fees - Dealer's Licences                      |     |
| Medical Device Establishment Licensing Fees                                | 65  |
| Fees to be Paid for the Examination of an Application in Respect of a Pest |     |
| Control Product  |     |
| Annual Charge (for a registered Pest Control Product)                      |     |
| Fees Charged for Filing a Claim for Exemption under the Hazardous Mater    |     |
| Information Review Act   |     |
| Cannabis Fees  |     |
| National Dosimetry Products and Services Fees                              |     |
| Master File Fees   |     |
| Certificate of Pharmaceutical Product Fee                                  |     |
| Endnotes   | 120 |

## Minister's message

On behalf of Health Canada, I am pleased to present the Departmental fees report for fiscal year 2021-22.

In 2021-22, Health Canada continued to ensure that Canadians had access to COVID-19 related medical devices. This was done by approving a third medical devices Ministerial Order which continues to allow Health Canada to waive related fees, expedite the authorization pathway for COVID-19 medical devices and provide flexibility and regulatory oversight to enable ongoing importation, sale and distribution of COVID-19 medical devices, including personal protective equipment.



In winter 2021, Health Canada held its first stakeholder information session since the new drugs and medical devices fees came into force on April 1, 2020. This was an opportunity for Health Canada to present the results of the 2020-21 Report on Fees, to discuss various business improvements initiatives the Department has put in place and to have an open dialogue with industry.

In spring 2022, Health Canada consulted on the proposed Biocides Regulations, related guidance document and proposed fees. The proposed regulations would bring disinfectants and surface sanitizers together under a single regulatory framework with a view to establishing a consistent simplified pathway to market authorization.

Health Canada conducted a review of the cannabis cost recovery framework and assessed the progress of cost recovery and the impact of the fee structure on the policy goals of the Cannabis Act and the cannabis industry. The review involved a series of internal analyses and consultations, as well as industry outreach in the form of a questionnaire and interviews. A summary report will be published in 2022-23.

Health Canada will continue to work towards ongoing transparency and accountability as it relates to fees. Through collaboration and evidence-based decision-making, I will continue to advance my key mandate priorities in order to maintain and improve the health and safety of all Canadians.

The Honourable Jean-Yves Duclos, P.C., M.P. Minister of Health

## About this report

This report, which is tabled under section 20 of the *Service Fees Act*<sup>i</sup>, the *Low-Materiality Fees Regulations*<sup>ii</sup>, and subsection 4.2.8 of the *Directive on Charging and Special Financial Authorities*<sup>iii</sup>, contains information about the fees that Health Canada had the authority to set in 2021–22.

The report covers fees that are subject to the *Service Fees Act* and exempted from the *Service Fees Act*.

For reporting purposes, fees are categorized by fee-setting mechanism. There are three mechanisms:

1. Act, regulation or fees notice
The authority to set these fees is delegated to a department, minister or Governor in
Council pursuant to an act of Parliament.

#### 2. Contract

Ministers have the authority to enter into contracts, which are usually negotiated between the minister and an individual or organization, and which cover fees and other terms and conditions. In some cases, that authority may also be provided by an act of Parliament.

#### 3. Market rate or auction

The authority to set these fees is pursuant to an act of Parliament or regulation, and the minister, department or Governor in Council has no control over the fee amount.

For fees set by act, regulation or fees notice, the report provides totals for fee groupings, as well as detailed information for each fee. Health Canada did not have fees set by contract, market rate or auction.

Although the fees Health Canada charges under the *Access to Information Act* were subject to the *Service Fees Act*, they are not included in this report. Information on Health Canada's access to information fees for 2021–22 is in our annual report<sup>iv</sup> to Parliament on the administration of the *Access to Information Act*.

## Remissions

In 2021–22, Health Canada was subject to the requirements to issue remissions under section 7 of the *Service Fees Act* and subsection 4.2.4 of the Treasury Board *Directive on Charging and Special Financial Authorities* to remit a fee, in whole or in part, to a fee payer when a service standard was deemed not met. Health Canada's remission policy and procedures, pursuant to the Service Fees Act, are on the following web page: Remissions for missed service standards<sup>v</sup>

In 2021–22, Health Canada also issued remissions under its enabling legislation. These remissions may have been for reasons other than not meeting a service standard.

The other sections of this report provide detailed amounts on Health Canada's remissions for 2021–22.

In addition to the remissions reported, Health Canada put in place a third COVID-19 medical devices interim order (effective until February 21, 2023) that maintains the same flexibilities as Interim Order No. 2 so that authorized COVID-19 medical devices can continue to be sold and imported in Canada. The first interim order was created on March 18, 2020, which was replaced by the second interim order on March 15, 2021.

## Overall totals, by fee setting mechanism

The following table presents the total revenue, cost and remissions for all fees that Health Canada had the authority to set in 2021–22, by fee-setting mechanism.

## Overall totals for 2021–22, by fee-setting mechanism

| Fee-setting mechanism                      | Revenue (\$) | Cost (\$)   | Remissions (\$) |
|--|--------------|-------------|-----------------|
| Fees set by act, regulation or fees notice | 274,128,683  | 584,854,381 | 120,739         |

# Totals, by fee grouping, for fees set by act, regulation or fees notice

A fee grouping is a set of fees relating to a single business line, directorate or program that a department had the authority to set for those activities.'

This section presents, for each fee grouping, the total revenue, cost and remissions for all fees that Health Canada had the authority to set in 2021-22 that are set by any of the following:

- act
- regulation
- fees notice

The revenue collections reported below may include: discontinued fees as of April 1, 2020; fees from previous years due to the timing of payments; and lower fees due to mitigation measures (as per the relevant regulations).

#### Fees for Right to Sell Drugs: totals for 2021-22

| Revenue (\$) | Cost (\$)  | Remissions (\$) |
|--------------|------------|-----------------|
| 28,571,438   | 82,280,531 | 0               |

## Fees for Right to Sell Licenced Class II, III, or IV Medical Devices: totals for 2021-22

| Revenue (\$) | Cost (\$)  | Remissions (\$) |
|--------------|------------|-----------------|
| 13,114,294   | 31,621,930 | 18,860          |

## Fees for Examination of a Submission - Drugs for Human Use: totals for 2021-22

| Revenue (\$) | Cost (\$)   | Remissions (\$) |
|--------------|-------------|-----------------|
| 71,849,968   | 163,902,742 | 25,324          |

#### Certificate of Supplementary Protection Application Fees: totals for 2021-22

| Revenue (\$) | Cost (\$) | Remissions (\$) |
|--------------|-----------|-----------------|
| 156,096      | 229,964   | 0               |

## Fees for Examination of Medical Device Licence Applications: totals for 2021-22

| Revenue (\$) | Cost (\$)  | Remissions (\$) |
|--------------|------------|-----------------|
| 7,459,566    | 21,897,541 | 1,600           |

## Fees for Examination of a Submission - Drugs for Veterinary Use Only: totals for 2021-22

| Revenue (\$) | Cost (\$)  | Remissions (\$) |
|--------------|------------|-----------------|
| 1,078,567    | 10,994,275 | 222             |

## Drug Establishment Licensing Fees: totals for 2021-22

| Revenue (\$) | Cost (\$)  | Remissions (\$) |
|--------------|------------|-----------------|
| 28,921,109   | 39,682,408 | 0               |

## Drug Establishment Licensing Fees - Dealer's Licences: totals for 2021-22

| Revenue (\$) | Cost (\$) | Remissions (\$) |
|--------------|-----------|-----------------|
| 568,605      | 7,412,718 | 0               |

## Medical Devices Establishment Licensing Fees: totals for 2021-22

| Revenue (\$) | Cost (\$)  | Remissions (\$) |
|--------------|------------|-----------------|
| 21,681,766   | 15,263,334 | 74,635          |

# Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product: totals for 2021-22

| Revenue (\$) | Cost (\$)  | Remissions (\$) |
|--------------|------------|-----------------|
| 6,962,776    | 51,494,952 | 98              |

#### Annual Charge (for a registered Pest Control Product): totals for 2021-22

| Revenue (\$) | Cost (\$)  | Remissions (\$) |
|--------------|------------|-----------------|
| 9,148,686    | 29,570,501 | 0               |

# Fees Charged for Filing a Claim for Exemption under the Hazardous Materials Information Review Act: totals for 2021-22

| Revenue (\$) | Cost (\$) | Remissions (\$) |
|--------------|-----------|-----------------|
| 432,522      | 3,625,445 | 0               |

#### Cannabis Fees: totals for 2021-22

| Revenue (\$) (note 1) | Cost (\$)   | Remissions (\$) |
|-----------------------|-------------|-----------------|
| 75,683,891            | 114,949,669 | 0               |

1) The Order Amending the Cannabis Fees Order (Extension of Deadline for Payment of 2020–2021 Annual Fee)<sup>vi</sup> provided short-term economic relief to the cannabis industry by deferring the annual fee payment due date from September 30, 2020 to March 31, 2021. Only revenues received by March 31, 2021 were reported in 2020-21. The remaining outstanding revenues are being reported in 2021-22.

The following fees are set under the Ministerial Authority to Enter into a Contract. Health Canada strives to recover 100% of costs for these services, however since the fees were last set increases to costs have been incurred.

#### National Dosimetry Products and Services Fees: totals for 2021-22

| Revenue (\$) | Cost (\$)  | Remissions (\$) |
|--------------|------------|-----------------|
| 7,454,835    | 10,035,163 | 0               |

#### Master File Fees: totals for 2021-22

| Revenue (\$) | Cost (\$) | Remissions (\$) |
|--------------|-----------|-----------------|
| 814,556      | 1,065,333 | 0               |

#### Certificate of Pharmaceutical Product Fee: totals for 2021-22

| Revenue (\$) | Cost (\$) | Remissions (\$) |
|--------------|-----------|-----------------|
| 230,008      | 827,875   | 0               |

# Details on each fee set by act, regulation or fees notice

This section provides detailed information on each fee that Health Canada had the authority to set in 2021-22 and that was set by any of the following:

- act
- regulation
- fees notice

The total of the revenue collections by fee grouping below may not equal the revenues reported in the "Totals, by fee grouping, for fees set by act, regulation or fees notice" section due to the following:

- Effective April 1, 2020, some fees were repealed from the *Financial Administration Act* and set under the authority of the *Food and Drugs Act*. In some instances, new fees were introduced and some fees were discontinued. Revenues collected after March 31, 2020 for discontinued fees are not included below; and
- A new report has been developed in the financial system to allow the reporting of revenue collections at the individual fee level, however, it is still being refined and therefore small discrepancies may exist.

## Fees for Right to Sell Drugs

Health Canada monitors human and veterinary drugs on the Canadian market through postmarket surveillance and compliance and enforcement activities. Industry pays an annual fee for the right to maintain and sell human and veterinary drugs in Canada.

#### Fee

- Human drugs Disinfectant (item 1)
- Human drugs Non-prescription (item 2)
- Human drugs Prescription (drug other than one referred to in item 1 or 2)

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)<sup>vii</sup>
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

20 calendar days to update the Drug Product Database following receipt of a complete Annual Notification Package

#### **Performance result**

100% (1,185/1,185 human and veterinary completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: All fees listed below

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|---|--|---|----------------------------|
| Human drugs - Disinfectant (item 1)   | 1,342                      | 1,388,587                               | 0  | April 1, 2023                           | 1,613                      |
| Human drugs - Non-<br>prescription (item 2)                                 | 2,018                      | 5,098,566                               | 0  | April 1, 2023                           | 3,109                      |
| Human drugs - Prescription (drug other than one referred to in item 1 or 2) | 2,749                      | 21,926,783                              | 0  | April 1, 2023                           | 5,158                      |

Veterinary Drugs

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

20 calendar days to update the Drug Product Database following receipt of a complete Annual Notification Package

#### **Performance result**

100% (1,185/1,185 human and veterinary completed within the service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Veterinary Drugs

| Fee              | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Veterinary Drugs | 367                        | 345,214                              | 0  | April 1, 2023                           | 528                        |

## Fees for Right to Sell a Licensed Class II, III or IV Medical Device

Health Canada monitors medical devices on the Canadian market through post-market surveillance and compliance and enforcement activities. There is an annual fee for the right to sell a Class II, III, IV medical device.

#### Fee

Medical Device Right to Sell

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

20 calendar days from deadline for receipt of annual notification to update the Medical Devices Licence Listing (MDALL) database

#### Performance result

99.34% (33,276/33,496 were completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Medical Device Right to Sell

| Fee                          | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|------------------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Medical Device Right to Sell | 381                        | 13,114,294                           | 18,860   | April 1, 2023                           | 421                        |

## Fees for Examination of a Submission — Drugs for Human Use

Before a drug is authorized for sale in Canada, Health Canada reviews it to assess its safety, efficacy and quality. Drug products include prescription and non-prescription pharmaceuticals, biologics, disinfectants and sanitizers with disinfectant claims.

#### Fee

New Active Substance

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

300 calendar days to complete Review 1

#### Performance result

100% (52/52 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: New Active Substance

| Fee                  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|----------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| New Active Substance | 437,009                    | 19,401,161                           | 0  | April 1, 2023                           | 565,465                    |

Clinical or non-clinical data and chemistry and manufacturing data

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

- For drugs under Division 1 of the Food and Drug Regulations: 210 calendar days to complete Review 1
- For drugs under Division 8 of the Food and Drug Regulations: 300 calendar days to complete Review 1

#### Performance result

- 210 calendar days 100% (1/1 completed within service standard)
- 300 calendar days 100% (55/55 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Clinical or non-clinical data and chemistry and manufacturing data

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Clinical or non-clinical data and chemistry and manufacturing data | 224,242                    | 8,535,125                            | 0  | April 1, 2023                           | 292,806                    |

Clinical or non-clinical data only

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

- For drugs under Division 1 of the Food and Drug Regulations: 210 calendar days to complete Review 1
- For drugs under Division 8 of the Food and Drug Regulations: 300 calendar days to complete Review 1

#### Performance result

- 210 calendar days 100% (1/1 completed within service standard)
- 300 calendar days 100% (157/157 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Clinical or non-clinical data only

| Fee                                | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|------------------------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Clinical or non-clinical data only | 95,796                     | 13,626,892                           | 0  | April 1, 2023                           | 117,080                    |

Comparative studies

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

- For drugs under Division 1 of the Food and Drug Regulations: 210 calendar days to complete Review 1
- For drugs under Division 8 of the Food and Drug Regulations: 180 calendar days to complete Review 1

#### Performance result

- 210 calendar days 100% (4/4 completed within service standard)
- 180 calendar days 100% (139/139 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Comparative studies

| Fee                 | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Comparative studies | 55,737                     | 8,777,956                            | 13,459                                   | April 1, 2023                           | 65,985                     |

Chemistry and manufacturing data only

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

- For drugs under Division 1 of the Food and Drug Regulations: 210 calendar days to complete Review 1
- For drugs under Division 8 of the Food and Drug Regulations: 180 calendar days to complete Review 1

#### Performance result

- 210 calendar days 100% (40/40 completed within service standard)
- 180 calendar days 99.7% (312/313 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Chemistry and manufacturing data only

| Fee                                   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---------------------------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Chemistry and manufacturing data only | 30,609                     | 10,123,957                           | 6,897  | April 1, 2023                           | 40,597                     |

Clinical or non-clinical data only, in support of safety upgrades to the labelling

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

120 calendar days to complete Review 1

#### Performance result

99.6% (277/278 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to *Service Fees Act*: Clinical or non-clinical data only, in support of safety upgrades to the labelling

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Clinical or non-clinical data only, in support of safety upgrades to the labelling | 19,404                     | 5,472,991                            | 4,861                                    | April 1, 2023                           | 21,429                     |

Labelling only

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

120 calendar days to complete Review 1

## Performance result

99.9% (899/900 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Labelling only

| Fee            | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|----------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Labelling only | 4,320                      | 4,098,833                            | 0  | April 1, 2023                           | 5,901                      |

Labelling only (generic drugs)

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

120 calendar days to complete Review 1

## **Performance result**

100% (126/126 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Labelling only (generic drugs)

| Fee                            | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--------------------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Labelling only (generic drugs) | 2,006                      | 228,616                              | 0  | April 1, 2023                           | 2,217                      |

Administrative submission

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

45 calendar days to review

## **Performance result**

99.6% (567/569 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Administrative submission

| Fee                       | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---------------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Administrative submission | 539                        | 271,454                              | 108  | April 1, 2023                           | 933                        |

Disinfectant - full review

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

- For drugs under Division 1 of the Food and Drug Regulations: 180 or 210 calendar days to complete Review 1
- For drugs under Division 8 of the Food and Drug Regulations: 300 calendar days to complete Review 1

#### Performance result

- 180/210 calendar days 100% (1/1 completed within service standard)
- 300 calendar days 100% (134/134 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Disinfectant - full review

| Fee                        | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|----------------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Disinfectant - full review | 7,126                      | 908,127                              | 0  | April 1, 2023                           | 12,297                     |

Labelling only (disinfectants)

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

90 calendar days to complete Review 1

## **Performance result**

100% (111/111 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Labelling only (disinfectants)

| Fee                            | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--------------------------------|----------------------------|--------------------------------------|---|---|----------------------------|
| Labelling only (disinfectants) | 2,502                      | 237,840                              | 0   | April 1, 2023                           | 2,764                      |

Drug identification number application - labelling standards

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

60 calendar days to complete Review 1

#### Performance result

100% (195/195 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Drug identification number application - labelling standards

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Drug identification number application - labelling standards | 1,613                      | 326,923                              | 0  | April 1, 2023                           | 1,782                      |

## **Certificate of Supplementary Protection Application Fees**

In agreeing to provisionally apply the Canada-European Union Comprehensive Economic and Trade Agreement (CETA), Canada has committed to provide up to two years of sui generis (of its own kind) protection for new pharmaceutical products protected by an eligible patent, from the expiry of the patent. Canada has implemented this commitment by introducing Certificates of Supplementary Protection (CSPs) for medicinal ingredients, applicable for Canadian pharmaceuticals, biologics and veterinary drugs.

#### Fee

Certificate of Supplementary Protection Application Fees

## Fee-setting authority

- *Patent Act*, 134(1)<sup>ix</sup>
- Certificate of Supplementary Protection Regulations (SOR/2017-165)<sup>x</sup>

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2020

#### Service standard

60 days for the first eligibility decision

#### **Performance result**

100% (17/17 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Certificate of Supplementary Protection Application Fees

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$)        | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|---|---|----------------------------|
| Certificate of<br>Supplementary Protection<br>Application Fees | 9,756                      | 156,096                              | This fee<br>was not<br>subject to<br>remissions | April 1, 2023                           | 10,152                     |

## Fees for Examination of an Application for a Medical Device Licence

The Medical Device Licence Application Fees apply only to Class II, III and IV medical device licence applications. The following types of medical devices are exempt from medical device licensing and therefore no fees apply: Class I medical devices; custom-made medical devices; medical devices for special access; and medical devices for investigational testing involving human subjects.

#### Fee

Applications for Class II licence

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

15 calendar days to review

## **Performance result**

99.1% (1,300/1,312 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Applications for Class II licence

| Fee                               | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|-----------------------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Applications for Class II licence | 478                        | 698,611                              | 1,427  | April 1, 2023                           | 589                        |

Applications for Class II licence amendment

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

15 calendar days to review

#### Performance result

99.6% (1,102/1,106 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Applications for Class II licence amendment

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Applications for Class II licence amendment | 272                        | 302,237                              | 136  | April 1, 2023                           | 302                        |

Applications for Class III licence

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

60 calendar days to complete Review 1

#### Performance result

99.6% (249/250 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Applications for Class III licence

| Fee                                | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|------------------------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Applications for Class III licence | 8,895                      | 2,017,737                            | 0  | April 1, 2023                           | 12,987                     |

Applications for Class III licence (near patient)

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

60 calendar days to complete Review 1

#### Performance result

100% (2/2 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Applications for Class III licence (near patient)

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Applications for Class III licence (near patient) | 16,032                     | 129,586                              | 0  | April 1, 2023                           | 27,666                     |

Applications for Class III licence amendment - changes in manufacturing

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

60 calendar days to complete Review 1

#### Performance result

100% (18/18 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to *Service Fees Act*: Applications for Class III licence amendment - changes in manufacturing

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Applications for Class III licence amendment - changes in manufacturing | 2,375                      | 39,477                               | 0  | April 1, 2023                           | 4,098                      |

Applications for Class III licence amendment - significant changes not related to manufacturing

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

60 calendar days to complete Review 1

#### Performance result

99.7% (301/302 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to *Service Fees Act*: Applications for Class III licence amendment - significant changes not related to manufacturing

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Applications for Class III licence amendment - significant changes not related to manufacturing | 7,543                      | 2,425,033                            | 0  | April 1, 2023                           | 10,425                     |

Applications for Class IV licence

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

75 calendar days to complete Review 1

#### Performance result

100% (38/38 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Applications for Class IV licence

| Fee                               | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|-----------------------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Applications for Class IV licence | 24,699                     | 1,013,882                            | 0  | April 1, 2023                           | 28,165                     |

Applications for Class IV licence amendment - changes in manufacturing

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

75 calendar days to complete Review 1

## **Performance result**

100% (36/36 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to *Service Fees Act*: Applications for Class IV licence amendment - changes in manufacturing

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Applications for Class IV licence amendment - changes in manufacturing | 2,375                      | 74,736                               | 0  | April 1, 2023                           | 4,098                      |

Applications for Class IV licence amendment - significant changes not related to manufacturing

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

75 calendar days to complete Review 1

#### Performance result

100% (91/91 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to *Service Fees Act*: Applications for Class IV licence amendment – significant changes not related to manufacturing

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Applications for Class IV licence amendment - significant changes not related to manufacturing | 9,964                      | 844,380                              | 0  | April 1, 2023                           | 14,902                     |

Applications for Class II, III or IV licence or licence amendment - private label medical device

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

15 calendar days to review

#### Performance result

99.5% (370/372 completed within service standard)

## Application of Low-Materiality Fees Regulations

Not subject to *Service Fees Act*: Applications for Class II, III or IV licence or licence amendment - private label medical device

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Applications for Class II,<br>III or IV licence or licence<br>amendment - private label<br>medical device | 147                        | 40,329                               | 37   | April 1, 2023                           | 163                        |

# Fees for Examination of a Submission — Drugs for Veterinary Use Only

Before a veterinary drug is authorized for sale in Canada, Health Canada reviews it to assess its efficacy and safety in the intended species as well as human safety. Fees are calculated on a component basis.

#### Fee

Drug Identification Number (Schedule 2 items 1 to 3)

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)<sup>vii</sup>
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

120 calendar days to complete Review 1

#### Performance result

100% (41/41 completed within service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|-----------------------|---|--|---|----------------------------|
| 1) Information, other than that referred to in item 2, to support an application for a number, including the submission of labelling material for a second review, if required | 1,146                 | 11,577                                  | 0  | April 1, 2023                           | 1,891                      |
| 2) Published references or other data  | 797                   | 0                                       | 0  | April 1, 2023                           | 1,314                      |

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------------|---|--|---|----------------------------|
| 3) Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug | 400                              | 5,000                                   | 0  | April 1, 2023                           | 658                        |

Notification - veterinary health product (Schedule 2 item 4)

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

30 calendar days to process notification

#### Performance result

99.6% (788/791 completed within service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|--------------------------------------|--|---|----------------------------------|
| 4) Information contained in a notification filed under subsection C.01.615(1) of the Food and Drug Regulations in respect of a veterinary health product | 486                              | 145,634                              | 122  | April 1, 2023                           | 538                              |

New drug submission (Schedule 2 items 5 to 18)

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

- 300 calendar days to complete Review 1 (items 5 to 17)
- 90 calendar days to complete Review 1 (item 18)

#### Performance result

- 300 calendar days 100% (7/7 completed within service standard)
- 90 calendar days 95% (19/20 completed within service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|---|--|---|----------------------------------|
| 5) Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species. (In the case of an antiparasitic drug, several indications in one food animal species.) | 25,419                           | 83,823                                  | 0  | April 1, 2023                           | 41,917                           |
| 6) Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one nonfood animal species  | 15,398                           | 12,342                                  | 0  | April 1, 2023                           | 25,392                           |

| Fee   | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|---|----------------------------------|---|--|---|----------------------------------|
| 7) Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration, dosage form and two indications in one animal species                                       | 36,966                           | 147,864                                 | 0  | April 1, 2023                           | 60,961                           |
| 8) Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species  | 50,057                           | 0                                       | 0  | April 1, 2023                           | 82,548                           |
| 9) Comparative<br>(pharmacodynamics, clinical or<br>bioavailability) data to support<br>an additional route of<br>administration  | 4,614                            | 0                                       | 0  | April 1, 2023                           | 7,610                            |
| 10) Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength  | 764                              | 0                                       | 0  | April 1, 2023                           | 1,261                            |
| 11) For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species | 34,660                           | 86,650                                  | 0  | April 1, 2023                           | 57,158                           |

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|---|--|---|----------------------------------|
| 12) For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species                          | 46,208                           | 0                                       | 0  | April 1, 2023                           | 76,201                           |
| 13) For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration  | 4,614                            | 0                                       | 0  | April 1, 2023                           | 7,610                            |
| 14) For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species | 23,096                           | 0                                       | 0  | April 1, 2023                           | 38,088                           |
| 15) Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug   | 7,700                            | 19,250                                  | 0  | April 1, 2023                           | 12,697                           |
| 16) Chemistry and manufacturing data to support one strength of a single dosage form   | 7,700                            | 48,521                                  | 0  | April 1, 2023                           | 12,697                           |

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|---|--|---|----------------------------------|
| 17) Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as item 16 | 3,851                            | 47,003                                  | 0  | April 1, 2023                           | 6,350                            |
| 18) Documentation to support a change of manufacturer  | 400                              | 3,640                                   | 100  | April 1, 2023                           | 658                              |

Supplement to a new drug submission (Schedule 2 items 19 to 37)

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

- 240 calendar days to complete Review 1 (items 19 to 36)
- 90 calendar days to complete Review 1 (item 37)

#### Performance result

- 240 calendar days 100% (20/20 completed within service standard)
- 90 calendar days 100% (1/1 completed within service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | fee amount (\$) | 2021-22<br>total fee<br>revenue<br>(\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|-----------------|---|--|---|----------------------------------|
| 19) Efficacy data to support an additional indication in one animal species  | 20,027          | 60,081                                  | 0  | April 1, 2023                           | 33,026                           |
| 20) Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one nonfood animal species | 15,398          | 30,796                                  | 0  | April 1, 2023                           | 25,392                           |
| 21) Efficacy and safety data (in<br>the intended species) to support<br>an indication in another animal<br>species   | 25,419          | 0                                       | 0  | April 1, 2023                           | 41,917                           |

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|---|--|---|----------------------------------|
| 22) Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species. | 36,966                           | 0                                       | 0  | April 1, 2023                           | 60,961                           |
| 23) Efficacy and safety data (in<br>the intended species) to support<br>a growth promotion or<br>production enhancement<br>indication in one animal species  | 50,057                           | 0                                       | 0  | April 1, 2023                           | 82,548                           |
| 24) Efficacy and safety data (in<br>the intended species) to support<br>the concurrent use of two drugs<br>approved for the same animal<br>species   | 12,312                           | 0                                       | 0  | April 1, 2023                           | 20,305                           |
| 25) Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration  | 4,614                            | 4,614                                   | 0  | April 1, 2023                           | 7,610                            |
| 26) Comparative<br>(pharmacodynamics, clinical or<br>bioavailability) data to support<br>each additional strength  | 764                              | 764                                     | 0  | April 1, 2023                           | 1,261                            |
| 27) For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species   | 4,614                            | 0                                       | 0  | April 1, 2023                           | 7,610                            |

| Fee   | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|---|----------------------------------|---|--|---|----------------------------------|
| 28) For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species | 23,096                           | 0                                       | 0  | April 1, 2023                           | 38,088                           |
| 29) For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period   | 11,548                           | 0                                       | 0  | April 1, 2023                           | 19,045                           |
| 30) For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required   | 9,243                            | 0                                       | 0  | April 1, 2023                           | 15,243                           |
| 31) Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process   | 7,700                            | 48,521                                  | 0  | April 1, 2023                           | 12,697                           |
| 32) Chemistry and manufacturing data to support a change in formulation or dosage form  | 3,851                            | 3,851                                   | 0  | April 1, 2023                           | 6,350                            |
| 33) Chemistry and manufacturing data to support a change in packaging or in the sterilization process   | 3,072                            | 6,144                                   | 0  | April 1, 2023                           | 5,065                            |

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|---|--|---|----------------------------------|
| 34) Chemistry and manufacturing data to support an extension of the expiry dating                              | 2,309                            | 0                                       | 0  | April 1, 2023                           | 3,807                            |
| 35) Chemistry and manufacturing data to support the concurrent use of two drugs                                | 2,309                            | 0                                       | 0  | April 1, 2023                           | 3,807                            |
| 36) Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage forms | 764                              | 2,292                                   | 0  | April 1, 2023                           | 1,261                            |
| 37) Documentation to support a change to the name of a manufacturer or the brand name of a drug                | 400                              | 800                                     | 0  | April 1, 2023                           | 658                              |

Abbreviated new drug submission (Schedule 2 items 38 to 42)

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

- 300 calendar days to complete Review (items 38 to 41)
- 90 calendar days to complete Review 1 (item 42)

#### Performance result

- 300 calendar days 100% (15/15 completed within service standard)
- 90 calendar days n/a (0/0 completed within service standard)

## Application of Low-Materiality Fees Regulations

| Fee   | fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|---|-----------------------|---|--|---|----------------------------------|
| 38) Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form  | 4,614                 | 4,614                                   | 0  | April 1, 2023                           | 7,610                            |
| 39) For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product | 4,614                 | 2,321                                   | 0  | April 1, 2023                           | 7,610                            |

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|---|--|---|----------------------------------|
| 40) Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug   | 7,700                            | 44,671                                  | 0  | April 1, 2023                           | 12,697                           |
| 41) Chemistry and manufacturing data to support a single dosage form   | 7,700                            | 67,315                                  | 0  | April 1, 2023                           | 12,697                           |
| 42) Documentation to support (a) a change of manufacturer, in the case of an abbreviated new drug submission; or (b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission | 400                              | 0                                       | 0  | April 1, 2023                           | 658                              |

Supplement to an abbreviated new drug submission (Schedule 2 items 38 to 42)

## **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

- 240 calendar days to complete Review 1 (items 38 to 41)
- 90 calendar days to complete Review 1 (item 42)

#### Performance result

- 240 calendar days 100% (3/3 completed within service standard)
- 90 calendar days n/a (0/0 completed within service standard)

## Application of Low-Materiality Fees Regulations

| Fee   | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|---|----------------------------------|---|--|---|----------------------------------|
| 38) Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form  | 4,614                            | 4,614                                   | 0  | April 1, 2023                           | 7,610                            |
| 39) For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product | 4,614                            | 2,321                                   | 0  | April 1, 2023                           | 7,610                            |

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|---|--|---|----------------------------------|
| 40) Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug   | 7,700                            | 44,671                                  | 0  | April 1, 2023                           | 12,697                           |
| 41) Chemistry and manufacturing data to support a single dosage form   | 7,700                            | 67,315                                  | 0  | April 1, 2023                           | 12,697                           |
| 42) Documentation to support (a) a change of manufacturer, in the case of an abbreviated new drug submission; or (b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission | 400                              | 0                                       | 0  | April 1, 2023                           | 658                              |

Preclinical submission (Schedule 2 items 43 to 50)

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

60 calendar days to complete Review 1

#### **Performance result**

Not applicable - no applications received

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | fee<br>amount<br>(\$) |
|--|----------------------------------|--------------------------------------|--|---|-----------------------|
| 43) Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dose form, route of administration and indication in one species   | 7,700                            | 0                                    | 0  | April 1, 2023                           | 12,697                |
| 44) Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated | 6,157                            | 0                                    | 0  | April 1, 2023                           | 10,153                |

| Fee   | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|---|----------------------------------|--------------------------------------|--|---|----------------------------------|
| 45) For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species                                | 23,096                           | 0                                    | 0  | April 1, 2023                           | 38,088                           |
| 46) For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species           | 34,660                           | 0                                    | 0  | April 1, 2023                           | 57,158                           |
| 47) For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species | 46,208                           | 0                                    | 0  | April 1, 2023                           | 76,201                           |
| 48) For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species                          | 11,548                           | 0                                    | 0  | April 1, 2023                           | 19,045                           |

| Fee   | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|---|----------------------------------|--------------------------------------|--|---|----------------------------------|
| 49) Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient | 7,700                            | 0                                    | 0  | April 1, 2023                           | 12,697                           |
| 50) Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient     | 3,851                            | 0                                    | 0  | April 1, 2023                           | 6,350                            |

Sale of new drug for emergency treatment (Schedule 2 items 51 and 52)

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

## Service standard

2 business days to review application

#### **Performance result**

100% (446/446 completed within service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|--------------------------------------|--|---|----------------------------------|
| 51) Information to support the sale of a drug to be used in the emergency treatment of a non-food-producing animal | 51                               | 11,577                               | 0  | April 1, 2023                           | 57                               |
| 52) Information to support the sale of a drug to be used in the emergency treatment of a food-producing animal     | 102                              | 7,650                                | 0  | April 1, 2023                           | 114                              |

Experimental studies certificate (Schedule 2 items 53 to 56)

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

60 calendar days to review application

#### Performance result

100% (127/127 completed within service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|--------------------------------------|--|---|----------------------------------|
| 53) Information and material to<br>support the issuance of an<br>experimental studies certificate<br>for a drug to be administered to<br>a non-food-producing animal   | 979                              | 25,946                               | 0  | April 1, 2023                           | 1,082                            |
| 54) Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal | 490                              | 2,450                                | 0  | April 1, 2023                           | 542                              |

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|--------------------------------------|--|---|----------------------------------|
| 55) Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal   | 2,953                            | 29,540                               | 0  | April 1, 2023                           | 3,262                            |
| 56) Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal | 490                              | 490                                  | 0  | April 1, 2023                           | 542                              |

Notifiable change (Schedule 2 item 57)

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

90 calendar days to review application

#### Performance result

100% (62/62 completed within service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|--------------------------------------|--|---|----------------------------------|
| 57) Information and material to support an application for Notifiable Change | 2,069                            | 94,226                               | 0  | April 1, 2023                           | 3,413                            |

Protocol (Schedule 2 item 58)

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

90 calendar days to review package

#### **Performance result**

100% (6/6 completed within service standard)

## Application of Low-Materiality Fees Regulations

| Fee   | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|---|----------------------------------|--------------------------------------|--|---|----------------------------------|
| 58) A protocol that is filed with the Minister and may support a new drug submission, an abbreviated new drug submission, a supplement to a new drug submission or abbreviated new drug submission, a preclinical submission or information and material that is filed for the purpose of obtaining an experimental studies certificate | 2,069                            | 9,523                                | 0  | April 1, 2023                           | 3,413                            |

## **Drug Establishment Licensing Fees**

Any person in Canada must obtain a Drug Establishment Licence (DEL) if they are engaged in any of the six regulated activities (fabricate, import, distribute, wholesale, package/label, and test) with respect to human and/or veterinary drugs. A fee is charged for the examination of a DEL application, including all compliance and enforcement and supporting activities needed to ensure that the applicant/licence holder conforms to all regulatory requirements. The DEL fee is calculated on a per-site basis, therefore, the fee amount varies by application. A DEL fee is charged for the application for a new DEL, an annual licence review of a DEL, certain amendments to a DEL, or reinstatement of a suspended DEL.

#### Fee

Human Drug Establishment Licence Fees

#### **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

## Year fee-setting authority was introduced

2017

## Last year fee-setting authority was amended

2021

#### Service standard

250 calendar days to issue/ renew license

## Performance result

100% (851/851) of licences issued (human and veterinary) within 250 calendar days

## Application of Low-Materiality Fees Regulations

| Fee                               | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$)<br>(note 1) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|-----------------------------------|----------------------------|--|--|---|----------------------------|
| Fabrication - Sterile dosage form | 41,647                     | 2,071,287  | 0  | April 1, 2023                           | 46,221                     |
| Importation                       | 28,975                     | 10,809,999                                       | 0  | April 1, 2023                           | 35,688                     |

| Fee                                   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$)<br>(note 1) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---------------------------------------|----------------------------|--|--|---|----------------------------|
| Fabrication - non-sterile dosage form | 28,308                     | 2,020,277  | 0  | April 1, 2023                           | 34,266                     |
| Distribution                          | 13,855                     | 704,508  | 0  | April 1, 2023                           | 18,215                     |
| Wholesaling                           | 6,159                      | 823,708  | 0  | April 1, 2023                           | 10,630                     |
| Packaging/labelling                   | 6,049                      | 625,628  | 0  | April 1, 2023                           | 6,681                      |
| Testing                               | 3,194                      | 178,492  | 0  | April 1, 2023                           | 5,514                      |
| Building outside Canada (each)        | 917                        | 11,057,531                                       | 0  | April 1, 2023                           | 1,014                      |

<sup>1)</sup> As of April 1, 2020, a new Drug Establishment Licencing fee structure was introduced, therefore the fee revenue reported above represents only those revenues collected based on the new fees. An additional amount of approximately \$0.4M was collected under the old fee structure.

Veterinary Drug Establishment Licence Fees

## Fee-setting authority

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

# Year fee-setting authority was introduced 2017

# Last year fee-setting authority was amended

2021

#### Service standard

250 calendar days to issue/renew license

#### Performance result

100% (851/851) of licences issued (human and veterinary) within 250 calendar days

## Application of Low-Materiality Fees Regulations

| Fee                                   | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) (note 1) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|---------------------------------------|----------------------------------|--|--|---|----------------------------------|
| Fabrication - Sterile dosage form     | 40,407                           | 80,605   | 0  | April 1, 2023                           | 45,262                           |
| Importation                           | 13,367                           | 392,846  | 0  | April 1, 2023                           | 23,066                           |
| Fabrication - non-sterile dosage form | 10,957                           | 61,413   | 0  | April 1, 2023                           | 18,905                           |
| Distribution                          | 6,031                            | 19,327   | 0  | April 1, 2023                           | 10,409                           |
| Wholesaling                           | 2,412                            | 42,133   | 0  | April 1, 2023                           | 4,161                            |
| Packaging/labelling                   | 6,049                            | 0  | 0  | April 1, 2023                           | 6,681                            |
| Testing                               | 1,641                            | 2,630  | 0  | April 1, 2023                           | 2,833                            |
| Building outside Canada (each)        | 917                              | 993,625  | 0  | April 1, 2023                           | 1,014                            |

<sup>1)</sup> As of April 1, 2020, a new Drug Establishment Licencing fee structure was introduced, therefore the fee revenue reported above represents only those revenues collected based on the new fees. An additional amount of approximately \$23K was collected under the old fee structure.

## **Drug Establishment Licensing Fees - Dealer's Licences**

Fees for the examination of a new dealer's licence application (Human Drugs), a new dealer's licence (Veterinary Drugs) or the renewal of a dealer's licence; issued under the Narcotic Control Regulations and Part G of the Food and Drug Regulations. There is no fee associated with the application for a new or renewal of a controlled substances licence issued under the Benzodiazepines and Other Targeted Substances Regulations and Part J of the Food and Drug Regulations.

#### Fee

- Dealer's Licence Fees Human Drugs
- Dealer's Licence Fees Veterinary Drugs

## Fee-setting authority

Financial Administration Act (FAA)xi

- Human Drugs: Fees in Respect of a Dealer's Licences Regulations (SOR/2011-79)<sup>xii</sup>
- Veterinary Drugs: *Licenced Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations* (SOR/98-5)<sup>xiii</sup>

# Year fee-setting authority was introduced 1998

## Last year fee-setting authority was amended

• Human Drugs: 2020

• Veterinary Drugs: 2022

#### Service standard:

- 270 Calendar days to issue a decision on an application for a **new** dealer's licence for controlled substances, from the receipt of a complete application
- 90 Calendar days to issue a decision on an application to **renew** a dealer's licence for controlled substances, from the receipt of a complete application

#### Performance result

- New: 20% (9/44) of applications were processed within the service standard
- Renew: 98% (158/162) of applications were processed within the service standard

## Application of Low-Materiality Fees Regulations

Material (>\$151): All fees listed below

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Dealer's Licence Fees -<br>Human Drugs                      | 5,502.00                   | 541,127                              | 0  | April 1, 2023                           | 5,726.00                   |
| Dealer's Licence Fees -<br>Veterinary Drugs                 | 1,820.62                   | 19,970                               | 0  | April 1, 2023                           | 2,010.53                   |
| Dealer's Licence Fees -<br>Veterinary Drugs – First<br>Year | 910.31                     | 1,750                                | 0  | April 1, 2023                           | 1,005.27                   |

## **Medical Device Establishment Licensing Fees**

A Medical Device Establishment Licence (MDEL) is required for the activities of importing or selling medical devices for human use in Canada with exceptions<sup>a</sup>. A fee is charged for the examination of an MDEL application, including all compliance and enforcement and supporting activities needed to ensure that the applicant/licence holder conforms to all regulatory requirements. The MDEL fee is a flat fee. The same fee is charged for an application for a new MDEL, an annual licence review of an MDEL, and the reinstatement of a suspended MDEL.

#### Fee

Medical Device Establishment Licensing Fees

#### **Fee-setting authority**

- Food and Drugs Act (FDA), 30.61(1)vii
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)viii

# Year fee-setting authority was introduced 2017

# Last year fee-setting authority was amended 2021

#### Service standard

120 calendar days to issue/ renew licence

#### Performance result

99.5% (4,277 / 4,298) of licenses issued within 120 calendar days

#### Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Application for new licence and annual review of licence

<sup>&</sup>lt;sup>a</sup> As per the Medical Devices Regulations, an MDEL is not required for: a retailer, a health care facility, a manufacturer of Class II, III or IV medical devices who only sells either medical devices for which they hold a valid licence, or medical devices subject to Parts 2 and 3 of the Regulations, a manufacturer of a Class I medical device who imports or distributes solely through a licensed establishment, a person solely selling medical devices subject to Parts 2 and 3 of the Regulations, or a dispenser.

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Application for new licence and annual review of licence | 4,581                      | 21,681,766<br>(note 1)               | 74,636   | April 1, 2023                           | 5,060                      |

<sup>1)</sup>Revenue for 2021-22 was exceptionally high due to various reasons, however it is expected that this is a single-year phenomenon, and revenue figures will normalize starting in 2022-23.

# Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product

No person shall manufacture, possess, handle, store, transport, import, distribute or use a pest control product that is not registered under the *Pest Control Products Act*, except as otherwise authorized under the Act or unless specifically exempted by the *Pest Control Products Regulations*. Fees for applications to register or to amend the registration of a pest control product are payable by component submitted. The fee payable is the sum of the fees for the submitted components in addition to the basic processing fee.

The following table reflects the total 2021-22 fee revenue by individual fee.

| Fee   | 2021-22 total<br>fee revenue<br>(\$) |
|---|--------------------------------------|
| Processing  | 1,212,854                            |
| Applications not Mentioned in Schedules   | 264,536                              |
| Renewal   | 131,992                              |
| Schedule 1: Fees for Applications to Register, or to Amend the Registration of, a Product Other Than a Semiochemical or Microbial Agent   | Pest Control                         |
| Product Chemistry – active ingredient   | 653,601                              |
| Product Chemistry – end-use product or manufacturing concentrate  | 393,442                              |
| Toxicology data accompanying an application to register a pest control product that contains a new active ingredient  | 667,906                              |
| Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains a registered active ingredient  | 34,262                               |
| Toxicology data-acute toxicity studies  | 198,719                              |
| Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient  | 215,893                              |
| Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary | 87,479                               |
| Exposure data-other   | 74,188                               |
| Metabolism data   | 201,286                              |

| Fee  | 2021-22 total<br>fee revenue<br>(\$) |
|--|--------------------------------------|
| Residue data   | 394,997                              |
| Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient   | 514,741                              |
| Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary       | 35,174                               |
| Environmental fate data-other  | 70,401                               |
| Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient   | 398,295                              |
| Environmental toxicology data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary | 9,608                                |
| Environmental toxicology data-other  | 1,668                                |
| Value and effectiveness data for a pest control product  | 191,149                              |
| Identification of compensable data   | 346,402                              |
| Schedule 2: Fees for Applications in Respect of a Pest Control Product that is a or Microbial Agent  | Semiochemical                        |
| Registration of a new active ingredient – food use   | 17,818                               |
| Registration of a new active ingredient – non-food use   | 3,312                                |
| Amendment of registration – new risk assessment necessary-environmental fate data, environmental toxicity data or exposure data  | 0                                    |
| Amendment of registration – data required, label changes   | 12,701                               |
| Amendment of registration – data required, other   | 7,536                                |
| Amendment of registration – no data required   | 4,733                                |
| Registration of new active ingredient  | 134                                  |
| Amendment of registration  | 2,823                                |
| Schedule 3: Fees for Other Applications in Respect of a Pest Control Product   | 1                                    |

| Fee   | 2021-22 total<br>fee revenue<br>(\$) |
|---|--------------------------------------|
| Research authorization – major crops, other than research authorizations set out in paragraphs (c) and (d)                        | 255,884                              |
| Research authorization – minor use crops, other than research authorizations set out in paragraphs (c) and (d)                    | 51,425                               |
| Research authorization – microbial agents, semiochemicals and any substance listed in subparagraph 1(d) (ii) of these regulations | 20,952                               |
| Research authorization – greenhouse crops and non-agricultural uses   | 17,121                               |
| Research notifications  | 4,842                                |
| Registration of active ingredient to be used in pest control product manufactured only for export                                 | 59,318                               |
| Amendment to Registration of active ingredient to be used in pest control product manufactured only for export                    | 0                                    |
| Specification of maximum residue limit for a previously unexamined pest control product   | 0                                    |
| Specification of maximum residue limit for an unregistered use of a previously examined pest control product                      | 128,301                              |

Note: A new report has been developed in the financial system to allow reporting collections per fee, however, it is still being refined. Therefore, the total of the revenues listed above does not equal the revenues reported in the *Totals*, by fee grouping, for fees set by act, regulation or fees notice section by \$277K.

Category A Component Based - 655 days of Review (Conventional Chemicals and Import Maximum Residue Limits)

## Fee-setting authority

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

#### Service standard

655 days of Review

#### Performance result

64% (9/14 applications met the service standard)

## Application of Low-Materiality Fees Regulations

Material (>\$151): All fees listed below

| Fee  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$)  | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--|----------------------------------|---------------------------------------|--|---|----------------------------------|
| Product Chemistry - active ingredient  | 5,277                            | See the total<br>fee revenue<br>table | 0  | April 1, 2023                           | 5,491                            |
| Product Chemistry - end-use product or manufacturing concentrate   | 2,939                            |                                       |  | April 1, 2023                           | 3,058                            |
| Toxicology data accompanying an application to register a pest control product that contains a new active ingredient | 82,058                           |                                       |  | April 1, 2023                           | 85,374                           |

| Fee   | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|---|----------------------------------|--------------------------------------|--|---|----------------------------------|
| Toxicology data accompanying an application to register a pest control product -or to amend a pest control product - that contains an registered active ingredient  | 17,136                           |                                      |  | April 1, 2023                           | 17,829                           |
| Toxicology data - acute toxicity studies  | 3,200                            |                                      |  | April 1, 2023                           | 3,330                            |
| Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient  | 18,942                           |                                      |  | April 1, 2023                           | 19,708                           |
| Exposure data accompanying an application to register a pest control product -or to amend the registration of a pest control product -that contains a registered active ingredient, when a new risk assessment is necessary | 6,235                            |                                      |  | April 1, 2023                           | 6,488                            |
| Metabolism data   | 31,331                           |                                      |  | April 1, 2023                           | 32,598                           |
| Residue data  | 17,146                           |                                      |  | April 1, 2023                           | 17,839                           |
| Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient  | 46,205                           |                                      |  | April 1, 2023                           | 48,073                           |

| Fee   | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|---|----------------------------------|--------------------------------------|--|---|----------------------------------|
| Environmental fate data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary       | 25,587                           |                                      |  | April 1, 2023                           | 26,621                           |
| Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient  | 40,352                           |                                      |  | April 1, 2023                           | 41,984                           |
| Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary | 25,644                           |                                      |  | April 1, 2023                           | 26,681                           |
| Value and effectiveness data for a pest control product   | 983                              |                                      |  | April 1, 2023                           | 1,024                            |
| Specification of maximum residue limit for a previously unexamined pest control product   | 135,805                          |                                      |  | April 1, 2023                           | 141,293                          |
| Specification of maximum residue limit for an unregistered use of a previously examined pest control product  | 17,146                           |                                      |  | April 1, 2023                           | 17,839                           |

| Fee        | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|------------|----------------------------------|--------------------------------------|--|---|----------------------------------|
| Processing | 1,229                            |                                      |  | April 1, 2023                           | 1,280                            |

Category A Component Based - 555 days (Reduced risk, other biopesticides, non-conventionals, non-straight-chain lepidopteran pheromone)

## **Fee-setting authority**

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

## Service standard

555 days of Review

#### Performance result

100% (9/9 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Product Chemistry - active ingredient  | 5,277                      | See the total fee revenue            | 0  | April 1, 2023                           | 5,491                      |
| Product Chemistry - end-<br>use product or<br>manufacturing<br>concentrate   | 2,939                      | table                                |  | April 1, 2023                           | 3,058                      |
| Toxicology data accompanying an application to register a pest control product that contains a new active ingredient | 82,058                     |                                      |  | April 1, 2023                           | 85,374                     |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Toxicology data accompanying an application to register a pest control product - or to amend a pest control product - that contains an registered active ingredient   | 17,136                     |                                      |  | April 1, 2023                           | 17,829                     |
| Toxicology data - acute toxicity studies  | 3,200                      |                                      |  | April 1, 2023                           | 3,330                      |
| Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient  | 18,942                     |                                      |  | April 1, 2023                           | 19,708                     |
| Exposure data accompanying an application to register a pest control product - or to amend the registration of a pest control product - that contains a registered active ingredient, when a new risk assessment is necessary | 6,235                      |                                      |  | April 1, 2023                           | 6,488                      |
| Metabolism data   | 31,331                     |                                      |  | April 1, 2023                           | 32,598                     |
| Residue data  | 17,146                     |                                      |  | April 1, 2023                           | 17,839                     |
| Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient  | 46,205                     |                                      |  | April 1, 2023                           | 48,073                     |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Environmental fate data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary       | 25,587                     |                                      |  | April 1, 2023                           | 26,621                     |
| Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient  | 40,352                     |                                      |  | April 1, 2023                           | 41,984                     |
| Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary | 25,644                     |                                      |  | April 1, 2023                           | 26,681                     |
| Value and effectiveness data for a pest control product   | 983                        |                                      |  | April 1, 2023                           | 1,024                      |
| Registration of a new active ingredient - food use  | 7,834                      |                                      |  | April 1, 2023                           | 8,151                      |
| Registration of a new active ingredient - non-food use  | 4,701                      |                                      |  | April 1, 2023                           | 4,892                      |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Amendment of registration - new risk assessment necessary - environmental fate data, environmental toxicity data or exposure data | 3,135                      |                                      |  | April 1, 2023                           | 3,262                      |
| Processing  | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category A Component Based - 470 days of Review (Microbials including User Requested Minor Use Registration (URMUR), and URMUR for conventional chemical, reduced risk, other biopesticides, non-conventionals, non-straight-chain lepidopteran pheromone)

## Fee-setting authority

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

#### Service standard

470 days of Review

#### **Performance result**

100% (8/8 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Product Chemistry - active ingredient  | 5,277                      | See the total fee revenue            | 0  | April 1, 2023                           | 5,491                      |
| Product Chemistry - end-<br>use product or<br>manufacturing<br>concentrate   | 2,939                      | table                                |  | April 1, 2023                           | 3,058                      |
| Toxicology data accompanying an application to register a pest control product that contains a new active ingredient | 82,058                     |                                      |  | April 1, 2023                           | 85,374                     |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Toxicology data accompanying an application to register a pest control product - or to amend a pest control product -that contains an registered active ingredient  | 17,136                     |                                      |  | April 1, 2023                           | 17,829                     |
| Toxicology data - acute toxicity studies  | 3,200                      |                                      |  | April 1, 2023                           | 3,330                      |
| Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient  | 18,942                     |                                      |  | April 1, 2023                           | 19,708                     |
| Exposure data accompanying an application to register a pest control product - or to amend the registration of a pest control product - that contains a registered active ingredient, when a new risk assessment is necessary | 6,235                      |                                      |  | April 1, 2023                           | 6,488                      |
| Metabolism data   | 31,331                     |                                      |  | April 1, 2023                           | 32,598                     |
| Residue data  | 17,146                     |                                      |  | April 1, 2023                           | 17,839                     |
| Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient  | 46,205                     |                                      |  | April 1, 2023                           | 48,073                     |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Environmental fate data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary       | 25,587                     |                                      |  | April 1, 2023                           | 26,621                     |
| Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient  | 40,352                     |                                      |  | April 1, 2023                           | 41,984                     |
| Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary | 25,644                     |                                      |  | April 1, 2023                           | 26,681                     |
| Value and effectiveness data for a pest control product   | 983                        |                                      |  | April 1, 2023                           | 1,024                      |
| Registration of a new active ingredient - food use  | 7,834                      |                                      |  | April 1, 2023                           | 8,151                      |
| Registration of a new active ingredient - non-food use  | 4,701                      |                                      |  | April 1, 2023                           | 4,892                      |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Amendment of registration - new risk assessment necessary - environmental fate data, environmental toxicity data or exposure data | 3,135                      |                                      |  | April 1, 2023                           | 3,262                      |
| Processing  | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category A Component Based - 285 days of Review (Straight-chain lepidopteran pheromones, including User Requested Minor Use Registration)

## **Fee-setting authority**

- Pest Control Products Act, 63<sup>xiv</sup>
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

## Service standard

285 days of Review

#### Performance result

N/A (0 applications completed in 2021-22)

## Application of Low-Materiality Fees Regulations

| Fee                                   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---------------------------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Registration of new active ingredient | 629                        | See the total fee revenue            | 0  | April 1, 2023                           | 655                        |
| Amendment of registration             | 316                        | table                                |  | April 1, 2023                           | 330                        |

Category A Component Based - Submissions with atypical timelines and joint reviews

### Fee-setting authority

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

Variable as per Management of Submission Policy Appendix I, table 1xvi

### **Performance result**

79% (15/19 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Product Chemistry - active ingredient  | 5,277                      | See the total fee revenue table      | 0  | April 1, 2023                           | 5,491                      |
| Product Chemistry - end-<br>use product or<br>manufacturing<br>concentrate   | 2,939                      | table                                |  | April 1, 2023                           | 3,058                      |
| Toxicology data accompanying an application to register a pest control product that contains a new active ingredient | 82,058                     |                                      |  | April 1, 2023                           | 85,374                     |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Toxicology data accompanying an application to register a pest control product - or to amend a pest control product - that contains an registered active ingredient   | 17,136                     |                                      |  | April 1, 2023                           | 17,829                     |
| Toxicology data - acute toxicity studies  | 3,200                      |                                      |  | April 1, 2023                           | 3,330                      |
| Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient  | 18,942                     |                                      |  | April 1, 2023                           | 19,708                     |
| Exposure data accompanying an application to register a pest control product - or to amend the registration of a pest control product - that contains a registered active ingredient, when a new risk assessment is necessary | 6,235                      |                                      |  | April 1, 2023                           | 6,488                      |
| Metabolism data   | 31,331                     |                                      |  | April 1, 2023                           | 32,598                     |
| Residue data  | 17,146                     |                                      |  | April 1, 2023                           | 17,839                     |
| Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient  | 46,205                     |                                      |  | April 1, 2023                           | 48,073                     |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Environmental fate data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary       | 25,587                     |                                      |  | April 1, 2023                           | 26,621                     |
| Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient  | 40,352                     |                                      |  | April 1, 2023                           | 41,984                     |
| Environmental toxicology data accompanying an application to register a pest control product, or to amend the registration of a pest control product, that contains a registered active ingredient, when a new risk assessment is necessary | 25,644                     |                                      |  | April 1, 2023                           | 26,681                     |
| Value and effectiveness data for a pest control product   | 983                        |                                      |  | April 1, 2023                           | 1,024                      |
| Registration of a new active ingredient - food use  | 7,834                      |                                      |  | April 1, 2023                           | 8,151                      |
| Registration of a new active ingredient - non-food use  | 4,701                      |                                      |  | April 1, 2023                           | 4,892                      |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Amendment of registration - new risk assessment necessary - environmental fate data, environmental toxicity data or exposure data | 3,135                      |                                      |  | April 1, 2023                           | 3,262                      |
| Registration of new active ingredient   | 629                        |                                      |  | April 1, 2023                           | 655                        |
| Amendment of registration   | 316                        |                                      |  | April 1, 2023                           | 330                        |
| Specification of maximum residue limit for a previously unexamined pest control product   | 135,805                    |                                      |  | April 1, 2023                           | 141,293                    |
| Specification of maximum residue limit for an unregistered use of a previously examined pest control product                      | 17,146                     |                                      |  | April 1, 2023                           | 17,839                     |
| Processing  | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category B Component Based - 425 days of Review (Conventional Chemicals including emergency use and New Import Maximum Residue Limits for previously assessed active ingredient)

### Fee-setting authority

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

#### Service standard

425 days of Review

#### **Performance result**

94% (154/163 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Product Chemistry - active ingredient   | 5,277                      | See the total fee revenue            | 0  | April 1, 2023                           | 5,491                      |
| Product Chemistry - end-<br>use product or<br>manufacturing<br>concentrate  | 2,939                      | table                                |  | April 1, 2023                           | 3,058                      |
| Toxicology data accompanying an application to register a pest control product - or to amend a pest control product - that contains an registered active ingredient | 17,136                     |                                      |  | April 1, 2023                           | 17,829                     |

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Toxicology data - acute toxicity studies   | 3,200                      |                                      |  | April 1, 2023                           | 3,330                      |
| Exposure data - other  | 5,646                      |                                      |  | April 1, 2023                           | 5,875                      |
| Metabolism data  | 31,331                     |                                      |  | April 1, 2023                           | 32,598                     |
| Residue data   | 17,146                     |                                      |  | April 1, 2023                           | 17,839                     |
| Environmental fate data - other  | 12,500                     |                                      |  | April 1, 2023                           | 13,005                     |
| Environmental toxicology data - other  | 2,671                      |                                      |  | April 1, 2023                           | 2,780                      |
| Value and effectiveness data for a pest control product  | 983                        |                                      |  | April 1, 2023                           | 1,024                      |
| Specification of maximum residue limit for an unregistered use of a previously examined pest control product | 17,146                     |                                      |  | April 1, 2023                           | 17,839                     |
| Processing   | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category B Component Based - 360 days of Review (Reduced risk, other biopesticides, non-conventionals, non-straight chain lepidopteran pheromone including emergency use)

## **Fee-setting authority**

- Pest Control Products Act, 63<sup>xiv</sup>
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

360 days of Review

#### Performance result

95% (21/22 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Product Chemistry - active ingredient   | 5,277                      | See the total fee revenue            | 0  | April 1, 2023                           | 5,491                      |
| Product Chemistry - end-<br>use product or<br>manufacturing<br>concentrate  | 2,939                      | table                                |  | April 1, 2023                           | 3,058                      |
| Toxicology data accompanying an application to register a pest control product - or to amend a pest control product - that contains an registered active ingredient | 17,136                     |                                      |  | April 1, 2023                           | 17,829                     |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Toxicology data - acute toxicity studies                      | 3,200                      |                                      |  | April 1, 2023                           | 3,330                      |
| Exposure data - other   | 5,646                      |                                      |  | April 1, 2023                           | 5,875                      |
| Metabolism data   | 31,331                     |                                      |  | April 1, 2023                           | 32,598                     |
| Residue data  | 17,146                     |                                      |  | April 1, 2023                           | 17,839                     |
| Environmental fate data - other                               | 12,500                     |                                      |  | April 1, 2023                           | 13,005                     |
| Environmental toxicology data - other                         | 2,671                      |                                      |  | April 1, 2023                           | 2,780                      |
| Value and effectiveness<br>data for a pest control<br>product | 983                        |                                      |  | April 1, 2023                           | 1,024                      |
| Amendment of registration - data required, label changes      | 1,568                      |                                      |  | April 1, 2023                           | 1,632                      |
| Amendment of registration - data required, other              | 1,256                      |                                      |  | April 1, 2023                           | 1,308                      |
| Processing  | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category B Component Based - 240 days of Review (Microbials and straight chain lepidopteran pheromones including emergency use)

## Fee-setting authority

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

240 days of Review

#### Performance result

100% (17/17 application met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Amendment of registration - data required, label changes | 1,568                      | See the total fee revenue table      | 0  | April 1, 2023                           | 1,632                      |
| Amendment of registration - data required, other         | 1,256                      |                                      |  | April 1, 2023                           | 1,308                      |
| Amendment of registration                                | 316                        |                                      |  | April 1, 2023                           | 330                        |

Category B Component Based - 158 days of Review (Streamlined; application rate changes, tank mixes, new pests or changes to level of control)

## **Fee-setting authority**

- Pest Control Products Act, 63<sup>xiv</sup>
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

158 days of Review

#### Performance result

98% (55/56 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Value and effectiveness data for a pest control product  | 983                        | See the total fee revenue table      | 0  | April 1, 2023                           | 1,024                      |
| Amendment of registration - data required, label changes | 1,568                      |                                      |  | April 1, 2023                           | 1,632                      |
| Amendment of registration - no data required, other      | 316                        |                                      |  | April 1, 2023                           | 330                        |
| Processing   | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category B Component Based - Submissions with atypical timelines and joint reviews

### Fee-setting authority

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

Variable as per Management of Submission Policy Appendix I, table 2xvi

### **Performance result**

100% (7/7 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |               |       |
|---|----------------------------|--------------------------------------|--|---|----------------------------|---------------|-------|
| Product Chemistry - active ingredient   | 5,277                      | See the total fee revenue            | 0  | April 1, 2023                           | 5,491                      |               |       |
| Product Chemistry - end-<br>use product or<br>manufacturing<br>concentrate  | 2,939                      | table                                | table  | 2,939 table                             |                            | April 1, 2023 | 3,058 |
| Toxicology data accompanying an application to register a pest control product - or to amend a pest control product - that contains an registered active ingredient | 17,136                     |                                      |  | April 1, 2023                           | 17,829                     |               |       |
| Toxicology data-acute toxicity studies  | 3,200                      |                                      |  | April 1, 2023                           | 3,330                      |               |       |

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Exposure data-other  | 5,646                      |                                      |  | April 1, 2023                           | 5,875                      |
| Metabolism data  | 31,331                     |                                      |  | April 1, 2023                           | 32,598                     |
| Residue data   | 17,146                     |                                      |  | April 1, 2023                           | 17,839                     |
| Environmental fate data - other  | 12,500                     |                                      |  | April 1, 2023                           | 13,005                     |
| Environmental toxicology data - other  | 2,671                      |                                      |  | April 1, 2023                           | 2,780                      |
| Value and effectiveness<br>data for a pest control<br>product  | 983                        |                                      |  | April 1, 2023                           | 1,024                      |
| Amendment of registration - data required, label changes   | 1,568                      |                                      |  | April 1, 2023                           | 1,632                      |
| Amendment of registration - data required, other   | 1,256                      |                                      |  | April 1, 2023                           | 1,308                      |
| Amendment of registration - no data required   | 316                        |                                      |  | April 1, 2023                           | 330                        |
| Amendment of registration  | 316                        |                                      |  | April 1, 2023                           | 330                        |
| Specification of maximum residue limit for an unregistered use of a previously examined pest control product | 17,146                     |                                      |  | April 1, 2023                           | 17,839                     |
| Processing   | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category C Component Based - 240 days of Review (New/Changes to Product Labels, Addition of Approved Minor Use, Similar Product)

## **Fee-setting authority**

- Pest Control Products Act, 63<sup>xiv</sup>
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

240 days of Review

#### Performance result

98% (347/353 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Amendment of registration - no data required | 316                        | See the total fee revenue table      | 0  | April 1, 2023                           | 330                        |
| Amendment of registration                    | 316                        |                                      |  | April 1, 2023                           | 330                        |
| Processing                                   | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category C Component Based - 180 days of Review (New/Changes to TGAI, ISP, MA or EP Product Chemistry, Administrative Changes, Administrative Re-instatement)

## **Fee-setting authority**

- Pest Control Products Act, 63<sup>xiv</sup>
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

180 days of Review

#### Performance result

100% (94/94 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Amendment of registration - no data required | 316                        | See the total fee revenue table      | 0  | April 1, 2023                           | 330                        |
| Amendment of registration                    | 316                        |                                      |  | April 1, 2023                           | 330                        |
| Processing                                   | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category C Component Based - Submissions with atypical timelines and joint reviews

### Fee-setting authority

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

Variable as per Management of Submission Policy Appendix I, table 3xvi

## Performance result

N/A (0 applications completed in 2021-22)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Amendment of registration - no data required | 316                        | See the total fee revenue table      | 0  | April 1, 2023                           | 330                        |
| Amendment of registration                    | 316                        |                                      |  | April 1, 2023                           | 330                        |
| Processing                                   | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category D Component Based - 253 days of Review (Registration Renewal)

### **Fee-setting authority**

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

## Service standard

253 days of Review (The number of days from the issuance of the renewal notice to March 15 of the following year)

#### Performance result

100% (1,061/1,061 applications met the service standard)

## Application of Low-Materiality Fees Regulations

Low-materiality (\$51-\$151): Registration Renewal

| Fee                  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|----------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Registration Renewal | 88                         | See the total fee revenue table      | 0  | April 1, 2023                           | 92                         |

Category D Component Based – 46 Days of Review (Registration/Amendment to Registration of active ingredient to be used in pest control product manufactured only for export)

## **Fee-setting authority**

- Pest Control Products Act, 63<sup>xiv</sup>
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

## Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

46 days of Review

#### Performance result

100% (7/7 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Registration of active ingredient to be used in pest control product manufactured only for export              | 8,474                      | See the total fee revenue table      | 0  | April 1, 2023                           | 8,817                      |
| Amendment to Registration of active ingredient to be used in pest control product manufactured only for export | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category D Component Based - 42 days of Review (Master Copies)

## **Fee-setting authority**

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# $\begin{array}{c} \textbf{Year fee-setting authority was introduced} \\ 2002 \end{array}$

# Last year fee-setting authority was amended 2018

### Service standard

42 days of Review

## Performance result

99% (66/67 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee        | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$)  | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|------------|----------------------------|---------------------------------------|--|---|----------------------------|
| Processing | 1,229                      | See the total<br>fee revenue<br>table | 0  | April 1, 2023                           | 1,280                      |

Category D Component Based - 10 days of Review (Private Labels)

## **Fee-setting authority**

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# $\begin{array}{c} \textbf{Year fee-setting authority was introduced} \\ 2002 \end{array}$

# Last year fee-setting authority was amended 2018

### Service standard

10 days of Review

## Performance result

100% (5/5 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee        | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$)  | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|------------|----------------------------|---------------------------------------|--|---|----------------------------|
| Processing | 1,229                      | See the total<br>fee revenue<br>table | 0  | April 1, 2023                           | 1,280                      |

Category E Component Based - 159 days of Review (Research Authorizations for New Technical Grade Active Ingredients)

## Fee-setting authority

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

159 days of Review

#### Performance result

84% (16/19 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue<br>(\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount (\$) |
|---|----------------------------|---|--|---|-------------------------------|
| Research authorization -<br>major crops, other than<br>research authorizations set<br>out in paragraphs (c) and<br>(d)            | 5,500                      | See the total fee revenue table         | 0  | April 1, 2023                           | 5,723                         |
| Research authorization -<br>minor use crops, other than<br>research authorizations set<br>out in paragraphs (c) and<br>(d)        | 5,500                      |   |  | April 1, 2023                           | 5,723                         |
| Research authorization - microbial agents, semiochemicals and any substance listed in subparagraph 1(d) (ii) of these regulations | 1,319                      |   |  | April 1, 2023                           | 1,373                         |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue<br>(\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount (\$) |
|---|----------------------------|---|--|---|-------------------------------|
| Research authorization - greenhouse crops and non-agricultural uses | 1,319                      |   |  | April 1, 2023                           | 1,373                         |

Category E Component Based - 69 days of Review (Research Authorizations for New Uses of Registered Active Ingredients)

## **Fee-setting authority**

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

69 days of Review

#### Performance result

97% (56/58 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22<br>fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount (\$) |
|--|-------------------------------|--------------------------------------|---|---|-------------------------------|
| Research authorization -<br>major crops, other than<br>research authorizations set<br>out in paragraphs (c) and (d)                              | 5,500                         | See the total fee revenue table      | 0   | April 1, 2023                           | 5,723                         |
| Research authorization -<br>minor use crops, other than<br>research authorizations set<br>out in paragraphs (c) and (d)                          | 5,500                         |                                      |   | April 1, 2023                           | 5,723                         |
| Research authorization -<br>microbial agents,<br>semiochemicals and any<br>substance listed in<br>subparagraph 1(d) (ii) of<br>these regulations | 1,319                         |                                      |   | April 1, 2023                           | 1,373                         |

| Fee  | 2021–22<br>fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount (\$) |
|--|-------------------------------|--------------------------------------|--|---|-------------------------------|
| Research authorization -<br>greenhouse crops and non-<br>agricultural uses | 1,319                         |                                      |  | April 1, 2023                           | 1,373                         |

Category E Component Based - 30 days of Review (Research Notification for Research Carried out in Canada)

## **Fee-setting authority**

- Pest Control Products Act, 63<sup>xiv</sup>
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

30 days of Review

#### Performance result

100% (65/65 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee                    | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$)  | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|------------------------|----------------------------|---------------------------------------|--|---|----------------------------|
| Research notifications | 270                        | See the total<br>fee revenue<br>table | 0  | April 1, 2023                           | 282                        |

Category F Component Based - 45 days of Review (Registration and amendments to registered pest control products via notification)

## **Fee-setting authority**

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

### Service standard

45 days of Review

#### Performance result

99% (927/931 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee                                     | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Applications not mentioned in schedules | 270                        | See the total fee revenue table      | 98   | April 1, 2023                           | 282                        |

Category L Component Based - 425 days of Review (Equivalency and data compensation assessment of end-use product and manufacturing concentrate with partial data package - conventional chemical)

## Fee-setting authority

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

# Year fee-setting authority was introduced 2002

# Last year fee-setting authority was amended 2018

#### Service standard

425 days of Review

#### **Performance result**

83% (66/80 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Product Chemistry - active ingredient   | 5,277                      | See the total fee revenue            | 0  | April 1, 2023                           | 5,491                      |
| Product Chemistry - end-<br>use product or<br>manufacturing<br>concentrate  | 2,939                      | table                                |  | April 1, 2023                           | 3,058                      |
| Toxicology data accompanying an application to register a pest control product -or to amend a pest control product -that contains an registered active ingredient | 17,136                     |                                      |  | April 1, 2023                           | 17,829                     |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Toxicology data-acute toxicity studies                  | 3,200                      |                                      |  | April 1, 2023                           | 3,330                      |
| Exposure data - other                                   | 5,646                      |                                      |  | April 1, 2023                           | 5,875                      |
| Metabolism data   | 31,331                     |                                      |  | April 1, 2023                           | 32,598                     |
| Residue data  | 17,146                     |                                      |  | April 1, 2023                           | 17,839                     |
| Environmental fate data - other                         | 12,500                     |                                      |  | April 1, 2023                           | 13,005                     |
| Environmental toxicology data - other                   | 2,671                      |                                      |  | April 1, 2023                           | 2,780                      |
| Value and effectiveness data for a pest control product | 983                        |                                      |  | April 1, 2023                           | 1,024                      |
| Identification of compensable data                      | 2,343                      |                                      |  | April 1, 2023                           | 2,438                      |
| Processing  | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category L Component Based - 365 days of Review (Equivalency and data compensation assessment of active ingredient, end-use product and manufacturing concentrate with no data)

## **Fee-setting authority**

- Pest Control Products Act, 63<sup>xiv</sup>
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

## Year fee-setting authority was introduced 2002

## Last year fee-setting authority was amended 2018

### Service standard

365 days of Review

#### Performance result

85% (82/97 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Product Chemistry - active ingredient                                      | 5,277                      | See the total fee revenue            | 0  | April 1, 2023                           | 5,491                      |
| Product Chemistry - end-<br>use product or<br>manufacturing<br>concentrate | 2,939                      | - table                              |  | April 1, 2023                           | 3,058                      |
| Identification of compensable data   | 2,343                      |                                      |  | April 1, 2023                           | 2,438                      |
| Processing   | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category L Component Based – 360 days of Review (Equivalency and data compensation assessment of end-use product and manufacturing concentrate with partial data package - reduced risk, other biopesticides, non-conventionals, non-straight chain lepidopteran pheromone)

### **Fee-setting authority**

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

## Year fee-setting authority was introduced 2002

## Last year fee-setting authority was amended 2018

#### Service standard

360 days of Review

### **Performance result**

N/A (0 applications completed in 2021-22)

## Application of Low-Materiality Fees Regulations

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Product Chemistry - active ingredient   | 5,277                      | See the total fee revenue table      | 0  | April 1, 2023                           | 5,491                      |
| Product Chemistry - end-<br>use product or<br>manufacturing<br>concentrate  | 2,939                      |                                      |  | April 1, 2023                           | 3,058                      |
| Toxicology data accompanying an application to register a pest control product -or to amend a pest control product -that contains an registered active ingredient | 17,136                     |                                      |  | April 1, 2023                           | 17,829                     |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Toxicology data-acute toxicity studies                        | 3,200                      |                                      |  | April 1, 2023                           | 3,330                      |
| Exposure data - other   | 5,646                      |                                      |  | April 1, 2023                           | 5,875                      |
| Metabolism data   | 31,331                     |                                      |  | April 1, 2023                           | 32,598                     |
| Residue data  | 17,146                     |                                      |  | April 1, 2023                           | 17,839                     |
| Environmental fate data - other                               | 12,500                     |                                      |  | April 1, 2023                           | 13,005                     |
| Environmental toxicology data - other                         | 2,671                      |                                      |  | April 1, 2023                           | 2,780                      |
| Value and effectiveness<br>data for a pest control<br>product | 983                        |                                      |  | April 1, 2023                           | 1,024                      |
| Identification of compensable data                            | 2,343                      |                                      |  | April 1, 2023                           | 2,438                      |
| Amendment of registration - data required, label changes      | 1,568                      |                                      |  | April 1, 2023                           | 1,632                      |
| Amendment of registration - data required, other              | 1,256                      |                                      |  | April 1, 2023                           | 1,308                      |
| Processing  | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

Category L Component Based 240 days of Review (Equivalency and data compensation assessment of end-use product and manufacturing concentrate with partial data package microbials and straight chain lepidopteran pheromone)

## Fee-setting authority

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

## Year fee-setting authority was introduced 2002

## Last year fee-setting authority was amended 2018

#### Service standard

240 days of Review

### **Performance result**

N/A (0 applications completed in 2021-22)

## Application of Low-Materiality Fees Regulations

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|---|---|----------------------------|
| Identification of compensable data                       | 2,343                      | See the total fee revenue table      | 0   | April 1, 2023                           | 2,438                      |
| Amendment of registration - data required, label changes | 1,568                      |                                      |   | April 1, 2023                           | 1,632                      |
| Amendment of registration - data required, other         | 1,256                      |                                      |   | April 1, 2023                           | 1,308                      |
| Amendment of registration                                | 316                        |                                      |   | April 1, 2023                           | 330                        |
| Processing   | 1,229                      |                                      |   | April 1, 2023                           | 1,280                      |

Category L Component Based – Applications with atypical timelines (Tailgaters, renegotiated timelines, synchronized timelines, coordination with Re-Evaluation)

## **Fee-setting authority**

- Pest Control Products Act, 63<sup>xiv</sup>
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

## Year fee-setting authority was introduced 2002

## Last year fee-setting authority was amended 2018

### Service standard

Variable as per Management of Submission Policy Appendix I, table 7xvi

#### Performance result

100% (3/3 applications met the service standard)

## Application of Low-Materiality Fees Regulations

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Product Chemistry - active ingredient   | 5,277                      | See the total fee revenue            | 0  | April 1, 2023                           | 5,491                      |
| Product Chemistry - end-<br>use product or<br>manufacturing<br>concentrate  | 2,939                      | table                                |  | April 1, 2023                           | 3,058                      |
| Toxicology data accompanying an application to register a pest control product -or to amend a pest control product -that contains an registered active ingredient | 17,136                     |                                      |  | April 1, 2023                           | 17,829                     |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Toxicology data-acute toxicity studies                        | 3,200                      |                                      |  | April 1, 2023                           | 3,330                      |
| Exposure data - other   | 5,646                      |                                      |  | April 1, 2023                           | 5,875                      |
| Metabolism data   | 31,331                     |                                      |  | April 1, 2023                           | 32,598                     |
| Residue data  | 17,146                     |                                      |  | April 1, 2023                           | 17,839                     |
| Environmental fate data - other                               | 12,500                     |                                      |  | April 1, 2023                           | 13,005                     |
| Environmental toxicology data - other                         | 2,671                      |                                      |  | April 1, 2023                           | 2,780                      |
| Value and effectiveness<br>data for a pest control<br>product | 983                        |                                      |  | April 1, 2023                           | 1,024                      |
| Identification of compensable data                            | 2,343                      |                                      |  | April 1, 2023                           | 2,438                      |
| Amendment of registration - data required, label changes      | 1,568                      |                                      |  | April 1, 2023                           | 1,632                      |
| Amendment of registration - data required, other              | 1,256                      |                                      |  | April 1, 2023                           | 1,308                      |
| Amendment of registration                                     | 316                        |                                      |  | April 1, 2023                           | 330                        |
| Processing  | 1,229                      |                                      |  | April 1, 2023                           | 1,280                      |

## **Annual Charge (for a registered Pest Control Product)**

A registrant must pay each year, in respect of every pest control product that is registered in their name on April 1 of the year, an annual charge. All registered products including technical grade active ingredients (TGAI), import for manufacturing and export program (IMEPs), private label products and master copies must pay the annual charge.

#### Fee

Annual Charge

## Fee-setting authority

- Pest Control Products Act, 63xiv
- Pest Control Products Fees and Charges Regulations (SOR/2017-9)xv

## Year fee-setting authority was introduced 2002

Last year fee-setting authority was amended 2018

### Service standard

100% of all invoices were issued by April 30, 2021

### Performance result

100%

### Application of Low-Materiality Fees Regulations

| Fee           | 2021–22 fee<br>amount (\$)  | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$)  |
|---------------|---|--------------------------------------|--|---|---|
| Annual Charge | The lesser of<br>\$3,745.27<br>and 4% of the<br>actual gross<br>revenue<br>during the<br>registrant's<br>preceding<br>fiscal year,<br>but not less<br>than \$104.03 | 9,148,686                            | 0  | April 1, 2023                           | The lesser of<br>\$4,135.95<br>and 4% of the<br>actual gross<br>revenue<br>during the<br>registrant's<br>preceding<br>fiscal year,<br>but not less<br>than \$114.88 |

## Fees Charged for Filing a Claim for Exemption under the Hazardous Materials Information Review Act

When a supplier or employer wants to be exempt from having to disclose confidential business information (CBI), such as the chemical identity of one or more trade-secret hazardous ingredients, they must file a claim for exemption with Health Canada.

#### Fee

- Original Claims
- Refiled Claims

Note: A 50% fee reduction is available for small businesses that meet certain criteria

### **Fee-setting authority:**

- Hazardous Materials Information Review Act, 48(2)\*\*\*\*
- Hazardous Materials Information Review Regulations (SOR/88-456)xviii

## Year fee-setting authority was introduced

1988

## Last year fee-setting authority was amended

2020

#### Service standard

Seven calendar days from the date of the receipt of a complete application, for the issuance of a registry number

### **Performance result**

100% of claims (original and refiled) were registered within the service standard of seven calendar days

## Application of Low-Materiality Fees Regulations

| Fee                            | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--------------------------------|----------------------------------|---|--|---|----------------------------------|
| Original Claim (up to 15)      | 1,872.64                         | 412,455                                 | 0  | April 1, 2023                           | 2,067.98                         |
| Original Claim (between 16-25) | 416.14                           |   |  | April 1, 2023                           | 459.56                           |
| Original Claim (26+)           | 208.07                           |   |  | April 1, 2023                           | 229.77                           |

| Fee                            | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24<br>fee<br>amount<br>(\$) |
|--------------------------------|----------------------------------|---|--|---|----------------------------------|
| Refiled Claims (up to 15)      | 1,498.11                         | 20,067                                  | 0  | April 1, 2023                           | 1,654.39                         |
| Refiled Claims (between 16-25) | 332.91                           |   |  | April 1, 2023                           | 367.64                           |
| Refiled Claims (26+)           | 166.46                           |   |  | April 1, 2023                           | 183.82                           |

### **Cannabis Fees**

Fees are charged for the following transactional activities: application screening, security clearances, and import/export permits. In addition, an Annual Regulatory Fee is charged which covers costs associated with a range of regulatory activities including regulatory inspections, compliance and enforcement, program management and oversight. These activities are carried out by Health Canada, the Canada Border Services Agency, the Public Health Agency of Canada and Public Safety Canada to support the objectives of the *Cannabis Act* with respect to the legislation and regulations of cannabis.

#### Fee

Licence Application Screening Fees

### Fee-setting authority

- Cannabis Act, 142(1)xix
- Cannabis Fees Order (SOR/2018-198)xx

## Year fee-setting authority was introduced 2018

## Last year fee-setting authority was amended 2020

#### Service standard

Health Canada is committed to a non-binding administrative service standard of 30-business-days for the screening of new licence applications. The standard excludes time spent awaiting additional information from applicants.

### Performance result

The non-binding administrative standard was met 94% of the time.

### Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: All fees listed below

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Licence Application Screening Fee - Licence for micro-cultivation | 1,706                      | 498,125                              | This fee<br>was not                      | April 1, 2023                           | 1,886                      |

| Fee   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Licence Application Screening Fee - Licence for standard cultivation      | 3,411                      | (note 1)                             | subject to remissions  | April 1, 2023                           | 3,767                      |
| Licence Application<br>Screening Fee - Licence<br>for a nursery           | 1,706                      |                                      |  | April 1, 2023                           | 1,886                      |
| Licence Application Screening Fee - Licence for micro-processing          | 1,706                      |                                      |  | April 1, 2023                           | 1,886                      |
| Licence Application Screening Fee - Licence for standard processing       | 3,411                      |                                      |  | April 1, 2023                           | 3,767                      |
| Licence Application Screening Fee - Licence for sale for medical purposes | 3,411                      |                                      |  | April 1, 2023                           | 3,767                      |

<sup>1)</sup>The revenues are significantly lower than previous fiscal years due to an increase in the number of micro and nursery licence holders in 2021-22 compared to the other years. These licence holders pay a lower fee, however, the cost of screening is the same for all licence classes.

Application for a Security Clearance

## **Fee-setting authority**

- *Cannabis Act*, 142(1)<sup>xix</sup>
- Cannabis Fees Order (SOR/2018-198)xx

## Year fee-setting authority was introduced 2018

## Last year fee-setting authority was amended 2020

### Service standard

No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the *Cannabis Fees Order*.

### **Performance result**

Not applicable

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Application for a Security Clearance

| Fee                                  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--------------------------------------|----------------------------|--------------------------------------|--|---|----------------------------|
| Application for a Security Clearance | 1,722                      | 3,466,560                            | This fee<br>was not<br>subject to<br>remissions              | April 1, 2023                           | 1,903                      |

Application for Import or Export Permit

### **Fee-setting authority**

- Cannabis Act, 142(1)xix
- Cannabis Fees Order (SOR/2018-198)xx

## Year fee-setting authority was introduced 2018

## Last year fee-setting authority was amended 2020

### Service standard

Health Canada commits to a non-binding administrative service standard of 30 business days from the date that payment is received for the application to the issuance or rejection of the permit. The standard excludes time spent awaiting additional information from applicants.

### Performance result

The non-binding administrative standard was met 95% of the time

### Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: Application for Import or Export Permit

| Fee                                     | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---|----------------------------|--------------------------------------|--|---|----------------------------|
| Application for Import or Export Permit | 636                        | 597,340                              | This fee<br>was not<br>subject to<br>remissions              | April 1, 2023                           | 703                        |

Annual Regulatory Fee

### Fee-setting authority

- Cannabis Act, 142(1)xix
- Cannabis Fees Order (SOR/2018-198)xx

## Year fee-setting authority was introduced 2018

## Last year fee-setting authority was amended 2020

#### Service standard

No administrative service standard for this fee as outlined during the 2018 consultation on the Proposed Approach to Cost Recovery for the Regulation of Cannabis and the subsequent Regulatory Impact Analysis Statement for the *Cannabis Fees Order*.

### Performance result

Not applicable

## Application of Low-Materiality Fees Regulations

Not subject to Service Fees Act: All fees listed below

| Fee  | 2021–22 fee<br>amount (\$)                                   | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$)                                   |
|--|--|---|--|---|--|
| Annual fee - Licence for micro-cultivation         | as<br>per <i>Cannabis</i><br><i>Fees Order</i> <sup>xx</sup> | 71,121,867                              | This fee was not   | Exempt                                  | as<br>per <i>Cannabis</i><br><i>Fees Order</i> <sup>xx</sup> |
| Annual fee - Licence for standard cultivation      |  | (note 1)                                | subject to remissions  |   |  |
| Annual fee - Licence for a nursery                 |  |   |  |   |  |
| Annual fee - Licence for micro-processing          |  |   |  |   |  |
| Annual fee - Licence for standard processing       |  |   |  |   |  |
| Annual fee - Licence for sale for medical purposes |  |   |  |   |  |

1)The Order Amending the Cannabis Fees Order (Extension of Deadline for Payment of 2020–2021 Annual Fee)<sup>vi</sup> provided short-term economic relief to the cannabis industry by deferring the annual fee payment due date from September 30, 2020 to March 31, 2021. Only revenues received by March 31, 2021 were reported in 2020-21. The remaining outstanding revenues are being reported in 2021-22.

## **National Dosimetry Products and Services Fees**

National Dosimetry Services (NDS) provides radiation monitoring services to Canadians who are exposed to radiation in their work environment. NDS provides commercial dosimetry services to over 100,000 individuals working in over 12,500 organizations and operates on a cost-recovery basis. There are a number of components to NDS that are billed on a regular basis. These fees include the annual support fee, the shipping and handling fee and the processing fee. Other fees are billed depending on whether additional services are requested or if a dosimeter is overdue, late, lost or damaged.

#### Fee

National Dosimetry Products and Services Fees

### Fee-setting authority

- Minister's Authority
- Fees notice published in Canada Gazette<sup>xxi</sup>

## Year fee-setting authority was introduced 2004

## Last year fee-setting authority was amended 2017

#### Service standard

Provide timely, responsive and reliable dosimetry services:

- 1. Exposures reported to the National Dose Registry within 45 calendar days of receipt Canadian Nuclear Safety Commission (CNSC) regulatory standard;
- 2. Dosimeters shipped 10-13 business days prior to exchange date with clients;
- 3. Dose results for whole body and extremity services reported to clients within internal service standards of 10- 20 business days, depending on the dosimetry service;
- 4. Client account information updated within two business days;
- 5. Client voice mails responded to within one business day; and
- 6. Client emails responded to within two business days.

#### Performance result

- 1. 100% compliance with the 45 day regulatory (CNSC) standard;
- 2. Shipped out 99% of dosimeters within 10 to 13 business days prior to exchange date;
- 3. 83% reported within internal standard of 10-20 business days, depending on the dosimetry service. Reduction due to COVID-19 pandemic impact on operations. CNSC regulatory standard prioritized over internal standards.;
- 4. 97% completed within two business days;
- 5. 92% being addressed within one business day; and
- 6. 92% addressed within two business days.

# **Application of** *Low-Materiality Fees Regulations*Not subject to section 17 of the *Service Fees Act*

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24   | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Annual support   | 85.00                      | Not<br>available                     | This fee<br>was not<br>subject to                            | Not subject to the Service Fees           | 85.00                      |
| Annual support - multi-<br>group discount<br>(5+ groups) | 50.00                      | Not<br>available                     | remissions   | Act and therefore no automatic annual     | 50.00                      |
| Shipping and handling (per shipment)                     | 14.50                      | Not<br>available                     |  | increase: All<br>fees                     | 14.50                      |
| Processing fees (per dosimeter)                          | 5.50 to 17.50              | Not<br>available                     |  | All fees<br>currently<br>under<br>review. | 5.50 to<br>17.50           |
| Ad hoc dosimeter request - add-on (per shipment)         | 65.00                      | Not<br>available                     |  |   | 65.00                      |
| Priority processing request (per request)                | 95.00                      | Not<br>available                     |  |   | 95.00                      |
| Pregnancy service (semi-<br>monthly)                     | 375.00                     | Not<br>available                     |  |   | 375.00                     |
| Electronic personal dosimeter rental (per year)          | 415.00                     | Not<br>available                     |  |   | 415.00                     |
| Specialized consultation (per hour)                      | 125.00                     | Not<br>available                     |  |   | 125.00                     |
| Customized reporting (per hour)                          | 60.00                      | Not<br>available                     |  |   | 60.00                      |
| NDR dose modifications (per hour)                        | 60.00                      | Not<br>available                     |  |   | 60.00                      |
| Reprinting reports (per report)                          | 10.00                      | Not<br>available                     |  |   | 10.00                      |

| Fee  | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--|----------------------------|--------------------------------------|--|---|----------------------------|
| Overdue dosimeter<br>(three months after<br>wearing period ends) | 55.00                      | Not<br>available                     |  |   | 55.00                      |
| Late dosimeter<br>(six months after wearing<br>period ends)      | 55.00                      | Not<br>available                     |  |   | 55.00                      |
| Lost/damaged dosimeter   | 82.50                      | Not<br>available                     |  |   | 82.50                      |
| Damaged electronic personal dosimeter                            | 415.00                     | Not<br>available                     |  |   | 415.00                     |
| Credit upon returning overdue dosimeter                          | 28.75                      | Not<br>available                     |  |   | 28.75                      |
| Credit upon returning late or lost dosimeter                     | 57.50                      | Not<br>available                     |  |   | 57.50                      |

### **Master File Fees**

A Master File (MF) is a reference that provides information about specific processes or components used in the manufacturing, processing, or packaging of a drug. The MF is a useful vehicle for providing information to Health Canada, where that information is confidential business information (CBI) and is not available to the manufacturer of the dosage form or to the sponsors of a drug submission, DIN (Drug identification Number) application or clinical trial application (CTA).

#### Fee

- New Master Files (file registration)
- Drug Master Files letter of access
- Drug Master Files Update

### Fee-setting authority

- Minister's Authority
- Fees notice published in Canada Gazette<sup>xxii</sup>

## Year fee-setting authority was introduced 1996

## Last year fee-setting authority was amended 2017

### Service standard

30 calendar days

#### **Performance result**

99.6% (2,014/2,022 issued within 30 calendar days)

### Application of Low-Materiality Fees Regulations

Not subject to section 17 of the Service Fees Act: All fees listed below

| Fee                                  | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | 2021-22<br>total<br>remissions<br>issued for<br>the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|--------------------------------------|----------------------------------|---|--|---|----------------------------|
| New Master Files (file registration) | 1,298                            | 372,326                                 | This fee<br>was not  | April 1, 2023                           | 1,351                      |
| Drug Master Files – letter of access | 184                              | 219,469                                 | subject to remissions  | April 1, 2023                           | 192                        |

| Fee                        | 2021–22<br>fee<br>amount<br>(\$) | 2021-22<br>total fee<br>revenue<br>(\$) | total remissions issued for the fee (\$) | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|----------------------------|----------------------------------|---|--|---|----------------------------|
| Drug Master Files - Update | 563                              | 257,823                                 |  | April 1, 2023                           | 587                        |

### **Certificate of Pharmaceutical Product Fee**

A certificate issued establishing the status of the pharmaceutical, biological, radiopharmaceutical or veterinary product listed and the Good Manufacturing Practice status of the fabricator of the product.

#### Fee

Certificate of Pharmaceutical Product

## Fee-setting authority

- Minister's Authority
- Fees notice published in Canada Gazettexxiii

## Year fee-setting authority was introduced 1996

## Last year fee-setting authority was amended 2012

### Service standard

25 business days to issue certificate

#### Performance result

96.6% (2,407 / 2,492 of certificates issued within 25 business days)

## Application of Low-Materiality Fees Regulations

Not subject to section 17 of the Service Fees Act: Certificate of Pharmaceutical Product

| Fee                                   | 2021–22 fee<br>amount (\$) | 2021-22<br>total fee<br>revenue (\$) | total remissions issued for the fee (\$)        | Fee<br>adjustment<br>date in<br>2023-24 | 2023-24 fee<br>amount (\$) |
|---------------------------------------|----------------------------|--------------------------------------|---|---|----------------------------|
| Certificate of Pharmaceutical Product | 94                         | 230,008                              | This fee<br>was not<br>subject to<br>remissions | April 1, 2023                           | 98                         |

### **Endnotes**

<sup>i</sup> Service Fees Act, <a href="https://laws-lois.justice.gc.ca/eng/acts/S-8.4/index.html">https://laws-lois.justice.gc.ca/eng/acts/S-8.4/index.html</a>

- iii Directive on Charging and Special Financial Authorities, <a href="https://laws-lois.justice.gc.ca/eng/regulations/SOR-2019-109/index.html">https://laws-lois.justice.gc.ca/eng/regulations/SOR-2019-109/index.html</a>
- iv Access to Information and Privacy <a href="https://www.canada.ca/en/health-canada/corporate/about-health-canada/reports-publications.html#atip">https://www.canada.ca/en/health-canada/corporate/about-health-canada/reports-publications.html#atip</a>
- v Remissions for missed service standards <a href="https://www.canada.ca/en/health-canada/services/funding/cost-recovery-service-fees.html#a6">https://www.canada.ca/en/health-canada/services/funding/cost-recovery-service-fees.html#a6</a>
- vi Order Amending the Cannabis Fees Order (Extension of Deadline for Payment of 2020–2021 Annual Fee): SOR/2020-170, <a href="https://gazette.gc.ca/rp-pr/p2/2020/2020-08-05/html/sor-dors170-eng.html">https://gazette.gc.ca/rp-pr/p2/2020/2020-08-05/html/sor-dors170-eng.html</a>
- vii Food and Drugs Act, https://laws-lois.justice.gc.ca/eng/acts/f-27/
- viii Fees in Respect of Drugs and Medical Devices Order, <u>Fees in Respect of Drugs and Medical Devices Order</u> (justice.gc.ca)
- ix Patent Act, https://laws-lois.justice.gc.ca/eng/acts/p-4/page-28.html#docCont
- <sup>x</sup> Certificate of Supplementary Protection Regulations (SOR/2017-165), <a href="https://laws-lois.justice.gc.ca/eng/regulations/SOR-2017-165/FullText.html">https://laws-lois.justice.gc.ca/eng/regulations/SOR-2017-165/FullText.html</a>
- xi Financial Administration Act, https://laws-lois.justice.gc.ca/eng/acts/f-11/
- xii Fees in Respect of Dealer's Licences Regulations (SOR/2011-79), <a href="https://laws-lois.justice.gc.ca/eng/regulations/sor-2011-79/page-1.html">https://laws-lois.justice.gc.ca/eng/regulations/sor-2011-79/page-1.html</a>
- xiii Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations, <a href="https://laws-lois.justice.gc.ca/eng/regulations/SOR-98-5/page-1.html">https://laws-lois.justice.gc.ca/eng/regulations/SOR-98-5/page-1.html</a>
- xiv Pest Control Products Act, https://laws-lois.justice.gc.ca/eng/acts/p-9.01/
- xv Pest Control Products Fees and Charges Regulations (SOR/2017-9), https://lawslois.justice.gc.ca/eng/regulations/SOR-2017-9/page-1.html#h-843512
- xvi Performance Timelines for Pest Control Product Applications, <a href="https://www.canada.ca/en/health-canada/services/consumer-product-safety/reports-publications/pesticides-pest-management/policies-guidelines/management-submissions-policy.html#a5">https://www.canada.ca/en/health-canada/services/consumer-product-safety/reports-publications/pesticides-pest-management/policies-guidelines/management-submissions-policy.html#a5</a>
- xvii Hazardous Materials Information Review Act, https://laws-lois.justice.gc.ca/eng/acts/h-2.7/index.html
- xviii Hazardous Materials Information Review Regulations (SOR/88-456), <a href="https://laws-lois.justice.gc.ca/eng/regulations/sor-88-456/">https://laws-lois.justice.gc.ca/eng/regulations/sor-88-456/</a>
- xix Cannabis Act, https://laws-lois.justice.gc.ca/eng/acts/c-24.5/

ii Low Materiality Regulations, https://laws-lois.justice.gc.ca/eng/regulations/SOR-2019-109/index.html

xx Cannabis Fees Order (SOR/2018-198), https://laws-lois.justice.gc.ca/eng/regulations/SOR-2018-198/page-1.html

xxi Notice amending Health Canada's National Dosimetry Services Products, Services and Fee Schedule, <a href="https://gazette.gc.ca/rp-pr/p1/2017/2017-01-28/html/notice-avis-eng.html">https://gazette.gc.ca/rp-pr/p1/2017/2017-01-28/html/notice-avis-eng.html</a>

xxii Notice of changes to Health Canada's Master File fees, <a href="https://canadagazette.gc.ca/rp-pr/p1/2017/2017-04-22/html/notice-avis-eng.html">https://canadagazette.gc.ca/rp-pr/p1/2017/2017-04-22/html/notice-avis-eng.html</a>

xxiii Notice amending Health Canada's Drug Master Files and Certificate of a Pharmaceutical Product fees, <a href="https://www.gazette.gc.ca/rp-pr/p1/2012/2012-02-18/html/notice-avis-eng.html#d104">https://www.gazette.gc.ca/rp-pr/p1/2012/2012-02-18/html/notice-avis-eng.html#d104</a>